Viridian Therapeutics, Inc. (LON:0K1R)
16.79
+0.27 (1.63%)
At close: Feb 21, 2025
Viridian Therapeutics Revenue
Viridian Therapeutics had revenue of $86.00K USD in the quarter ending September 30, 2024, with 19.44% growth. This brings the company's revenue in the last twelve months to $302.00K, down -12.97% year-over-year. In the year 2023, Viridian Therapeutics had annual revenue of $314.00K, down -82.28%.
Revenue (ttm)
$302.00K
Revenue Growth
-12.97%
P/S Ratio
n/a
Revenue / Employee
$3.21K
Employees
94
Market Cap
1.02B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 314.00K | -1.46M | -82.28% |
Dec 31, 2022 | 1.77M | -1.19M | -40.20% |
Dec 31, 2021 | 2.96M | 1.91M | 182.19% |
Dec 31, 2020 | 1.05M | -3.41M | -76.46% |
Dec 31, 2019 | 4.46M | -3.92M | -46.80% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
GSK plc | 31.38B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
Hikma Pharmaceuticals | 2.39B |
ConvaTec Group | 1.74B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Viridian Therapeutics News
- 16 days ago - Viridian Therapeutics Announces Inducement Grants for New Employees - GuruFocus
- 16 days ago - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease - Business Wire
- 2 months ago - Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade) - Seeking Alpha
- 2 months ago - Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation - Seeking Alpha
- 2 months ago - Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade) - Seeking Alpha
- 2 months ago - Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday - Benzinga
- 2 months ago - Viridian stock soars 25% on Phase 3 data for veligrotug - Seeking Alpha